(Mary Ann Liebert, Inc./Genetic Engineering News) A pilot study of guanfacine, a controlled-release alpha2-agonist, in children and adolescents with general, separation-related, and social anxiety disorder showed the drug to be safe and well-tolerated and provided preliminary evidence of its potential effectiveness.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2mKNvbo
No comments:
Post a Comment